Interaction between the hepatitis C virus and the immune system

Seminars in Liver Disease

Volumn 20, Issue 2, 2000, Pages 127-141

  Rehermann, B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cytotoxic; Hepatitis C; Immune response; Liver; T cell

Indexed keywords

CHIMPANZEE; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033861585     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9946     Document Type: Review

References (190)

1. Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology
2. Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA
3. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C
4. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: Specific detection of negative-strand viral RNA in various tissues
5. Does the hepatitis C virus replicate in cells of the hematopoietic lineage?
6. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR
7. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver
8. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection
9. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor
10. CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system
11. Binding of hepatitis C virus to CD81
12. Internal ribosome entry sites within the RNA genomes of hepatitis C virus and other flaviviruses
13. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
14. Variability of hepatitis C virus
15. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
16. Control of early viral and bacterial distribution and disease by natural antibodies
17. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture antibodies: Reevaluation of the role of HCV in liver disease
18. Antibody response to pre-S2 and hepatitis B virus induced liver damage
19. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells
20. Shutting down HIV
21. Poliovirus
22. A vigorous HCV-helicase specific T helper response dominates in the liver of a chimpanzee during acute self-limited hepatitis C
23. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3
24. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
25. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures
26. Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus
27. Hypervariable regions in the putative glycoprotein of hepatitis C virus
28. Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: Humoral immune response to hypervariable region 1
29. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins
30. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
31. B cell epitopes on the hepatitis C virus nucleocapsid protein determined by human monospecific antibodies
32. Vaccination of chimpanzees against infection by the hepatitis C virus
33. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells
34. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C
35. Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response
36. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus
37. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus
38. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy
39. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees
40. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus
41. Hepatic suppression of sensitization to antigen absorbed into the portal system
42. Combined liver and pancreas transplantation induces pancreas allograft tolerance
43. RAG1, RAG2 and pre-T cell receptor alpha chain expression by adult human hepatic T cells: Evidence for extrathymic T cell maturation
44. RAG1 and RAG2 expression in human intestinal epithelium: Evidence of extrathymic T cell differentiation
45. Different expression of the recombination activity gene RAG-1 in various populations of thymocytes, peripheral T cells and gut thymus-independent intraepithelial lymphocytes suggests two pathways of T cell receptor rearrangement
46. Intra-epithelial lymphocytes. Evidence for regional specialization and extrathymic T cell maturation in the human gut epithelium
47. Prometheus through the looking glass: Reflections on the hepatic immune system
48. Extramedullary erythropoiesis in human liver grafts
49. Proliferation and apoptosis of B220+CD4-CD8-TCR alpha beta intermediate T cells in the liver of normal adult mice: Implication for l pr pathogenesis
50. The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo
51. Expansion of the population of double negative CD4-8- T alpha beta- cells in the liver is a common feature of autoimmune mice
52. Extrathymic origin of intestinal intraepithelial lymphocytes bearing T-cell antigen receptor gamma delta
53. NK1.1+ T cell receptor-alpha/beta+ cells: New clues to their origin, specificity, and function
54. CD1 recognition by mouse NK1+ T lymphocytes
55. Role of early cytokines, including alpha and beta interferons (IFN- alpha/beta), in innate and adaptive immune responses to viral infections
56. IFN induction and associated changes in splenic leukocyte distribution
57. Interferons and other cytokines
58. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection
59. Nitric oxide and macrophage function
60. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein lalpha (MIP-lalpha)-dependent pathways
61. TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma
62. Mechanisms for virus-induced liver disease: Tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection
63. NK ceil receptors
64. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-l molecules
65. Immunohistochemical analysis of HLA (A,B,C) antigens in liver disease using a monoclonal antibody
66. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
67. Cytotoxic T-cell immunity to virus-infected non-baematopoietic cells requires presentation of exogenous antigen
68. Distinct functional phenotypes of cloned la-restricted helper T cells
69. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
70. A conditioned dendritic cell can be a temporal bridge between a cD4+ T-helper and a T-killer cell
71. Viral clearance without destruction of infected cells during acute HBV infection
72. Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection
73. Evidence for CD8+ T-cell immunity to murine rotavirus in the absence of perforin, fas and gamma interferon
74. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice
75. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
76. Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
77. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
78. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
79. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: Implications for vaccine development
80. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
81. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C
82. Analysis of a successful immune response against hepatitis C virus
83. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia
84. The developmental biology of T lymphocytes
85. Cell mediated immune response to the hepatitis C virus
86. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
87. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif
88. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
89. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis
90. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
91. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C
92. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-1ike supertype
93. Several HLA alleles share overlapping peptide specificities
94. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs
95. Definition of an HLA-A3-1ike supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules
96. Presence of effector CDg+ T cells in hepatitis C virus-exposed healthy seronegative donors
97. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response, disease activity and viral load in patients with chronic hepatitis C virus infection
98. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
99. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
100. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection
101. Differential cytotoxic T lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
102. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
103. Immune pathogenesis of hepatocellular carcinoma
104. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver
105. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
106. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Thls) and Th2s
107. Regulation of human interleukin 8 gene expression and binding of several other members of the intercrine family to receptors for interleukin-8
108. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines
109. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins
110. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells
111. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans
112. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease
113. Selective retention of activated CD8+ T cells by the normal liver
114. Intermittence of blood flow in liver sinusoids, studied by high-resolution in vivo microscopy
115. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia
116. Dynamics of intrahepatic lymphocytes in chronic hepatitis C: Enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis
117. Lymphocyte subsets and B2 microglobulin expression in chronic hepatitis C/nonAnonB: Effect of interferon-alpha treatment
118. Analysis of lymphocyte subsets in liver biopsy specimens with lymphoid follicle like structures
119. Immunopathobiology of chronic hepatitis C virus infection
120. Intrahepatic lymphocyte subpopulations and HLA class antigen expression by hepatocytes in chronic hepatitis C
121. Compartmentalization of T-lymphocyte to the site of disease: Intrahepatic CD4+ T-cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis
122. Analysis of T-cell receptor V beta repertoire in liver-infiltrating lymphocytes in chronic hepatitis C
123. Chronic hepatitis C. Analysis of host immune response by immunohistochemistry
124. Expression of cytokine-dependent immune adhesion molecules by hepatocytes
125. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C
126. Role of Fas ligand in apoptosis induced by hepatitis C virus infection
127. T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions
128. The pathophysiology of tumor necrosis factors
129. A novel addition to the T cell repertory: Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells
130. Perforin, fas/fas ligand and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL
131. Unequal death in T helper cell (Th) 1 and Th2 effectors: Th 1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis
132. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: Enrichment for V alpha24+ T cells and rapid elimination of effector cells by apoptosis
133. Non-A, and non-B hepatitis transmission in chimpanzees: A project of the transfusion-transmitted viruses study group
134. Determining the size of non-A, non-B hepatitis virus by filtration
135. Transmission of hepatitis C by intrahepatic inocculation with transcribed RNA
136. Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic la and 2a chimeras
137. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee
138. An infectious molecular clone of a Japanese genotype lb hepatitis C virus
139. Transmissible agent in non-A, non-B hepatitis
140. The pathology of viral hepatitis lin chimpanzees
141. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles
142. Comparative features of hepatitis C virus infection in humans and chimpanzees
143. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
144. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
145. Thema: Virushepatitis
146. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1
147. Identification of A2-restricted hepatitis C virns-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome
148. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses
149. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model
150. Transgenic expression of hepatitis C virus structural proteins in the mouse
151. Hepatitis C virus core and E2 protein expression in transgenic mice
152. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice
153. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice
154. Expression of hepatitis C virus envelope proteins in transgenic mice
155. Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice
156. Hepatitis C virus viremia in SCID → BNX mouse chimera
157. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals
158. Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro
159. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway
160. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatic C virus persistence
161. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor
162. Direct interaction of hepatitis C virus core protein with the cellular lymphocotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor
163. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein
164. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein
165. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HUH-7 cells
166. Hepatitis C virus core protein cooperates with ms and transforms primary rat embryo fibroblasts to tumorigenic phenotype
167. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes
168. Participation of endogenons tumor necrosis factor alpha in host resistance to cytomegalovirus infection
169. Identification of Rantes, MIP-1 alpha and MIP-1 beta as the major HIV-snppressive factors produced by CD8+ T cells
170. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA
171. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice
172. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
173. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase
174. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling
175. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance
176. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
177. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase
178. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
179. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype lb hepatitis C virus
180. Interferon resistance of hepatitis C virus genotype lb: Relationship to nonstructural 5A gene quasispecies mutations
181. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response
182. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus
183. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: Variability and stability
184. The origin of hepatitis C virus genotypes
185. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV) Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C
186. Quasispecies nature of hepatitis C virus and response to alpha interferon: Significance as a predictor of direct response to interferon
187. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
188. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
189. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
190. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope